Home  |  Contact

Cellosaurus Reh (CVCL_1650)

Cell line name Reh
Synonyms REH
Accession CVCL_1650
Resource Identification Initiative To cite this cell line use: Reh (RRID:CVCL_1650)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Doubling time: 34.7 hours (PubMed=8847894); 30 hours (PubMed=25984343); ~50-70 hours (DSMZ).
Microsatellite instability: Instable (MSI-high) (Sanger).
Omics: Array-based CGH.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Disease Childhood B acute lymphoblastic leukemia (NCIt: C9140)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_8857 (EU-1)CVCL_0011 (KM-3)CVCL_8462 (NOI-90)
Sex of cell Female
Age at sampling 15Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; PubMed=25877200

CSF1PO10,11,12 (ATCC; PubMed=25877200)
12,13 (CLS; Cosmic-CLP; DSMZ)
D5S81811,13 (ATCC; PubMed=25877200)
11,12,13 (CLS)
11,12 (Cosmic-CLP; DSMZ)
D8S117913,16 (CLS)
13,15 (PubMed=25877200)
D13S31711,13 (ATCC; PubMed=25877200)
11,12,13 (CLS)
11,14 (Cosmic-CLP)
10,11,14 (DSMZ)
D16S5399 (ATCC; PubMed=25877200)
9,10,13 (CLS)
9,13 (Cosmic-CLP; DSMZ)
D18S5110,13,14 (CLS)
10,14 (PubMed=25877200)
D21S1127,28,29,30,31 (CLS)
28,30 (PubMed=25877200)
FGA22,23,24 (CLS)
22,23 (PubMed=25877200)
Penta D9,10,12 (CLS)
9,11 (PubMed=25877200)
Penta E10,11 (CLS)
7,11 (PubMed=25877200)
TH017 (ATCC; CLS; PubMed=25877200)
7,9 (Cosmic-CLP; DSMZ)
vWA14,15 (ATCC; CLS; Cosmic-CLP; PubMed=25877200)
14,15,16 (DSMZ)
Web pages http://www.proteinatlas.org/learn/cellines

PubMed=197411; DOI=10.1038/267841a0
Rosenfeld C., Goutner A., Choquet C., Venuat A.M., Kayibanda B., Pico J.L., Greaves M.F.
Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line.
Nature 267:841-843(1977)

Zhou M., Gu L., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)

Zhou M., Yeager A.M., Smith S.D., Findley H.W.
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Blood 85:1608-1614(1995)

Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Leukemia 10:1592-1603(1996)

PubMed=9067587; DOI=10.1038/sj.leu.2400571
Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A., Janssen J.W.G., Drexler H.G.
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Leukemia 11:441-447(1997)

Findley H.W., Gu L., Yeager A.M., Zhou M.
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Blood 89:2986-2993(1997)

PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2
Matsuo Y., Drexler H.G.
Establishment and characterization of human B cell precursor-leukemia cell lines.
Leuk. Res. 22:567-579(1998)

PubMed=9823951; DOI=10.1038/sj.leu.2401198
Zhou M., Gu L., Yeager A.M., Findley H.W.
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Leukemia 12:1756-1763(1998)

PubMed=10490826; DOI=10.1038/sj.onc.1202874
Fu X., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.
EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1.
Oncogene 18:4920-4929(1999)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=16523483; DOI=10.1002/gcc.20317
Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Dexter T., Ashworth A., Kearney L.
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Genes Chromosomes Cancer 45:554-564(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cell line collections ATCC; CRL-8286
BCRJ; 0321
CLS; 300320/p630_REH
Cell line databases/resources CLDB; cl4132
CCRID; 3131C0001000700131
Cosmic-CLP; 909696
GDSC; 909696
Lonza; 58
Ontologies BTO; BTO:0001163
CLO; CLO_0008781
CLO; CLO_0008782
Biological sample resources BioSample; SAMN03471040
BioSample; SAMN03473380
Chemistry resources ChEMBL-Cells; CHEMBL3308823
ChEMBL-Targets; CHEMBL2366320
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM236802
GEO; GSM236838
GEO; GSM482492
GEO; GSM499514
GEO; GSM499538
GEO; GSM499727
GEO; GSM499733
GEO; GSM887530
GEO; GSM888612
GEO; GSM931330
GEO; GSM931331
GEO; GSM1195448
GEO; GSM1374847
GEO; GSM1670369
Other Wikidata; Q29958043
Polymorphism and mutation databases Cosmic; 798668
Cosmic; 801720
Cosmic; 909696
Cosmic; 919149
Cosmic; 991551
Cosmic; 994183
Cosmic; 996287
Cosmic; 998706
Cosmic; 999751
Cosmic; 1012114
Cosmic; 1037725
Cosmic; 1067440
Cosmic; 1118468
Cosmic; 1130244
Cosmic; 1191700
Cosmic; 1483360
Cosmic; 1524815
Cosmic; 2491075
Cosmic; 2523595
Cosmic; 2649233